Genentech beefs up its PD-L1 combo pipeline, signing the 'don’t eat me' specialists at Forty Seven
After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
